Beta Drugs Q1 FY27 Revenue Rises 25% as Profit Grows

Q1 performance shows broad-based improvement

Beta Drugs Ltd reported a strong set of financial results for the first quarter of FY27, with growth in both revenue and profitability. Revenue for the quarter stood at ₹125.55 crore, representing growth of 25.29% year-on-year and 33.62% quarter-on-quarter. The quarterly revenue figure was described as the highest in the company’s recent history. Net profit rose to ₹15.80 crore, up 35.04% from a year earlier and 74.59% sequentially. The results indicate that earnings grew faster than sales during the quarter. This was supported by a significant improvement in operating profitability. The company’s operating margin reached 21.80%, its highest level in recent quarters. The Q1 numbers place Beta Drugs’ operational performance in focus as it expands its presence across oncology, exports, APIs and contract manufacturing activities.

Revenue reaches ₹125.55 crore

The company recorded quarterly revenue of ₹125.55 crore in Q1 FY27. On a year-on-year basis, this represented an increase of 25.29%. Revenue also rose 33.62% compared with the preceding quarter, showing a sharp sequential recovery. The company’s latest quarterly sales level provides the base for its H1 FY27 revenue of ₹263.04 crore. Beta Drugs has said that its business is supported by multiple segments rather than a single product category. Its branded oncology business, export operations, API business and CMO activities are key components of the operating mix. The quarterly revenue growth is notable because the company has also reported production disruptions related to debottlenecking and capacity expansion at its Adley Formulations plant. These activities affected sales in the first half, according to the company’s communication.

Profit growth outpaces revenue growth

Net profit for Q1 FY27 was ₹15.80 crore. The figure increased 35.04% year-on-year, exceeding the 25.29% rise in revenue. Sequential profit growth was higher at 74.59%, against the 33.62% quarter-on-quarter increase in sales. This gap between revenue and profit growth points to improved operating leverage and cost control during the quarter. The operating margin of 21.80% was also the highest reported in recent quarters. Higher profitability is important for a pharmaceutical manufacturer because earnings can be affected by product mix, raw-material costs, manufacturing utilisation and regulatory spending. Beta Drugs’ Q1 outcome suggests that margin performance improved alongside the expansion in turnover. The company also reported a return on equity of 53.00%, indicating a high reported return relative to shareholders’ equity.

Key Q1 FY27 financial figures

H1 results provide additional context

Beta Drugs subsequently reported H1 FY27 revenue of ₹263.04 crore, compared with ₹203.60 crore in H1 FY26. This translates into year-on-year revenue growth of 29.2% for the six-month period. Consolidated EBITDA rose to ₹61 crore from ₹47 crore in the earlier-year period. EBITDA margin expanded to 23.18%, broadly in line with the 23.2% figure highlighted by the company. Profit after tax, excluding minority interest, increased to ₹34.30 crore from ₹23.90 crore. Gross margin improved to 56.2% in H1 FY27 from 51.4% in H1 FY26. The half-year data supports the trend visible in the Q1 results, where profitability rose alongside revenue. It also provides a wider view of the company’s margin improvement through the first half of the financial year.

Branded oncology and exports remain important

The company said its branded oncology segment grew 17% in H1 FY27. It is targeting ₹150 crore of revenue from its own branded business during FY27. Beta Drugs also reported four product launches in the branded business during the first half and said six more were planned. Five brands have annual sales above ₹5 crore, according to the company’s disclosures. Export sales were ₹43 crore in H1 FY27, while the business recorded 35 approvals and 76 dossier filings during the period. Four of the new dossiers were filed in Europe. The company said exports rebounded in Q2, with 95% growth during that quarter. Management expects export revenue to grow 30% in FY27, supported by existing orders and potential tender wins.

API, CMO and Nivian businesses add diversification

Beta Drugs said its API business grew by about 29% to 30% in H1 FY27. The company has also identified CMO activity as an important contributor to its business mix. In a separate Q1 performance summary, the company cited growth in branded oncology, Nivian and CMO operations, with CMO supported by proprietary Novel Drug Delivery Systems. The Nivian business recorded 75% year-on-year growth in H1 FY27, with revenue rising from ₹18 crore to ₹31 crore. The company said its top five brands account for about 63% of Nivian sales. Management is targeting more than 50% growth in Nivian during FY27. These businesses provide different sources of growth across domestic formulations, exports, active pharmaceutical ingredients and contract manufacturing.

Capacity work affected some sales

The H1 update also highlighted an operational constraint. Production shutdowns linked to debottlenecking and capacity expansion at the Adley Formulations plant affected sales, according to Beta Drugs. Such shutdowns can temporarily restrict manufacturing output even when demand remains firm. The company has not provided a quantified impact of the production interruptions in the available information. However, its H1 revenue still rose 29.2% year-on-year despite this issue. The margin expansion during the same period suggests that the company maintained cost discipline while carrying out operational work. Investors will track whether capacity-related actions improve future manufacturing flexibility and support volumes. The disclosed results show that the business continued to grow while these changes were under way.

FY27 guidance sets a benchmark

Management has maintained its expectation of FY27 revenue of ₹535 crore or more. It has also guided for EBITDA margin in the range of 23% to 24% for the full year. The H1 revenue of ₹263.04 crore represents close to half of this stated annual revenue objective. The reported H1 EBITDA margin of 23.18% sits within the guided range. This makes margin retention an important measure for the remaining part of FY27. The company has also set a medium-term growth target of 20% to 22% for branded oncology. Its operating priorities include product launches, export registrations, capacity expansion and growth in the acquired Nivian business. These stated targets will be assessed against future quarterly disclosures.

What the Q1 result means for investors

Beta Drugs’ Q1 FY27 results showed revenue growth, faster net-profit growth and a stronger operating margin. Revenue of ₹125.55 crore and net profit of ₹15.80 crore established a positive start to the financial year. The 21.80% operating margin and 53.00% return on equity were notable reported profitability indicators. The subsequent H1 data showed that revenue and EBITDA momentum continued through the first six months. At the same time, the company has flagged global market uncertainty and temporary production disruption from capacity-related work. Its FY27 revenue guidance of ₹535 crore or more and EBITDA margin target of 23% to 24% remain the key benchmarks for upcoming results. The next earnings updates will indicate whether segment growth and capacity actions continue to support these targets.